Combination therapy for advanced liver cancer after first treatment
Part of Cancer clinical trials.
This trial tests a new combination of treatments for people with advanced hepatocellular carcinoma (a type of liver cancer) whose cancer has gotten worse after their first treatment. It combines liver-directed chemotherapy (HAIC), an immunotherapy (TQB2868), and a targeted therapy (ramucirumab) to see if they work better together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 80 years old.
- You must have advanced liver cancer that has gotten worse after or you could not tolerate your first treatment.
- You must have at least one tumor that has not been treated and can be measured on scans.
- You have not had HAIC (a type of chemotherapy into the liver) with oxaliplatin before.
- You must be in generally good health (able to do daily activities) and have adequate liver and blood function.
- You cannot have other major medical problems like uncontrolled heart disease, active infections, or bleeding risks from varices.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—an immunotherapy (TQB2450), a targeted therapy (anlotinib), and a repeat HAIC infusion—for people whose advanced liver cancer has worsened after a first treatment. It may be an option if you've already had HAIC with platinum and are now looking for a new approach.
This trial tests a combination of three treatments for a rare form of liver cancer that is both hepatocellular and cholangiocarcinoma: HAIC (chemotherapy given directly into the liver artery), Camrelizumab (an immunotherapy that helps your immune system attack cancer cells), and Rivoceranib (a targeted therapy that blocks blood vessel growth to tumors). It may be an option if you haven't had prior systemic therapy for this cancer and your liver function is stable.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests a combination of liver-directed chemotherapy (HAIC) with the immunotherapy drugs atezolizumab and bevacizumab for people with liver cancer that cannot be surgically removed. It aims to see if this combination can shrink tumors and improve outcomes.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This trial tests a combination of immunotherapy (iparomlimab/tuvonralimab), a targeted drug (bevacizumab), and radiation (SBRT) plus liver-directed chemo (HAIC) for people with advanced liver cancer (HCC) that has spread to blood vessels or a few other places. It aims to see if this approach can help control the cancer.
Hear when a new Hepatocellular Carcinoma，Bispecific Antibodies, HAIC, Ramucirumab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.